SCHEMBL1885586

SCHEMBL1885586

O=c1c2sc3ccccc3c2n(Cc2ccccc2Br)c(=O)n1O

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TP53 P04637 10/20 0.55
MAPT P10636 5/20 0.55
RXFP1 Q9HBX9 2/20 0.54
THRB P10828 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.45
GAA P10253 1/20 0.43
ERCC5 P28715 1/20 0.42
FEN1 P39748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890325 0.84 TP53 (0.55) TP53MAPTRXFP1THRBSMN1; SMN2
SCHEMBL1882663 0.83 RXFP1 (0.64) TP53MAPTRXFP1THRBSMN1; SMN2
SCHEMBL1893700 0.83 RXFP1 (0.78) TP53MAPTRXFP1THRBGAA
SCHEMBL1888933 0.81 MAPT (0.60) TP53MAPTRXFP1THRBGAA
SCHEMBL1889926 0.78 RXFP1 (0.53) TP53MAPTRXFP1THRBSMN1; SMN2
SCHEMBL1887674 0.78 TP53 (0.64) TP53MAPTRXFP1THRBGAA
SCHEMBL1887765 0.76 RXFP1 (0.63) TP53MAPTRXFP1THRBGAA
SCHEMBL1890523 0.76 RXFP1 (0.60) TP53MAPTRXFP1THRBSMN1; SMN2
SCHEMBL1887201 0.76 TP53 (0.56) TP53MAPTRXFP1THRBERCC5
SCHEMBL1889858 0.76 TP53 (0.70) TP53MAPTRXFP1THRBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 US claimed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 US claimed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 WO claimed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 US disclosed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 US disclosed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 US disclosed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof FEN1, UNG, POLH TP53 476/4885MAPT 4773/4885RXFP1 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.